Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation
Autor: | B. Géry, Idlir Licaj, Audrey Rambeau, Anna Rose Johnson, D. de Raucourt, Juliette Thariat, C. Florescu, Emmanuel Babin, Radj Gervais |
---|---|
Přispěvatelé: | Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Service de recherche clinique [Centre François Baclesse], UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Radiothérapie [Centre François Baclesse], Service d'Oto-Rhino-Laryngologie (O.R.L.) et de Chirurgie Cervico-Faciale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN) |
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Adult
Male medicine.medical_specialty [SDV]Life Sciences [q-bio] Cetuximab chemistry.chemical_element Gastroenterology Disease-Free Survival Carboplatin Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans In patient 030223 otorhinolaryngology Aged Retrospective Studies Cisplatin Squamous Cell Carcinoma of Head and Neck business.industry Head and neck cancer Chemoradiotherapy Acute Kidney Injury Middle Aged medicine.disease Head and neck squamous-cell carcinoma 3. Good health Otorhinolaryngology chemistry Head and Neck Neoplasms 030220 oncology & carcinogenesis Female Surgery Neoplasm Recurrence Local Previously treated business Platinum medicine.drug |
Zdroj: | European Annals of Otorhinolaryngology, Head and Neck Diseases European Annals of Otorhinolaryngology, Head and Neck Diseases, Elsevier Masson, 2019, 136, pp.257-261. ⟨10.1016/j.anorl.2019.04.007⟩ |
ISSN: | 1879-7296 1879-730X |
DOI: | 10.1016/j.anorl.2019.04.007⟩ |
Popis: | Objective To evaluate platinum rechallenge efficacy and tolerance in patients presenting recurrent head and neck squamous cell carcinoma (HNSCC) after platinum-based chemoradiation. Materials and methods We retrospectively included all patients treated from 2007 to 2016 by platinum-based polychemotherapy for recurrence of HNSCC previously treated by primary or postsurgical platinum-based chemoradiation. The primary end-point was disease control rate (DCR) on platinum rechallenge. Results Forty-five patients were included. Median disease-free interval (DFI) after chemoradiation was 5.7 months. DCR on platinum rechallenge was 40%. Progression-free survival at recurrence was 3.7 months and overall survival 5.0 months. DCR in patients with recurrence within 6 months of chemoradiotherapy was 47.8%. DFI > 4.5 months was associated with better DCR: 28.5% versus 54.8%; P = 0.0311. Conclusion Platinum rechallenge provided good DCR in recurrent HNSCC after chemoradiation. |
Databáze: | OpenAIRE |
Externí odkaz: |